Cargando…
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder promoted by the constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr-Abl-inhibitor imatinib represents the first-line therapy against CML, almost 20-30% of patients develop chemotherapeutic resi...
Autores principales: | Salizzato, Valentina, Borgo, Christian, Cesaro, Luca, Pinna, Lorenzo A., Donella-Deana, Arianna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951282/ https://www.ncbi.nlm.nih.gov/pubmed/26919095 http://dx.doi.org/10.18632/oncotarget.7569 |
Ejemplares similares
-
Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells
por: Zanin, Sofia, et al.
Publicado: (2012) -
CK2 modulates adipocyte insulin-signaling and is up-regulated in human obesity
por: Borgo, Christian, et al.
Publicado: (2017) -
Generation and quantitative proteomics analysis of CK2α/α’((−/−)) cells
por: Borgo, Christian, et al.
Publicado: (2017) -
Exploring the CK2 Paradox: Restless, Dangerous, Dispensable
por: Franchin, Cinzia, et al.
Publicado: (2017) -
RpS3 Is Required for Spermatogenesis of Drosophila melanogaster
por: Fang, Yang, et al.
Publicado: (2023)